TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32736596
Drug: nebulised heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulised heparin
Study: 35045185
Drug: Fosnetupitant (FosNTP)
Normalized name: fosnetupitant
DrugBank: Fosnetupitant (DB14019)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosnetupitant (FosNTP) 235 mg
Study: 35045185
Drug: Fosaprepitant (FosAPR)
DrugBank: Fosaprepitant (DB06717)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fosaprepitant (FosAPR) 150 mg
Study: 33930859
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with 1 treatment-related SAE
Study: 33930859
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment with 2 or more treatment-related SAEs
Study: 35624452
Drug: Intravenous sildenafil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous sildenafil
Study: 32828993
Drug: Wider implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wider implants (3.3 × 11.5 mm vs 4.2 × 11.5 mm)
Study: 35640431
Drug: Fenfluramine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenfluramine (0.2 mg/kg/day, titrated to a maximum of 0.7 mg/kg/day or 0.4 mg/kg/day with stiripentol)
Study: 33838113
Drug: Voxelotor 1500
Normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Voxelotor 1500 mg
Study: 33838113
Drug: Voxelotor 900
Normalized name: Voxelotor
DrugBank: Voxelotor (DB14975)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Voxelotor 900 mg
Study: 35258154
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets 3.5 mg/kg (early cladribine)
Study: 35258154
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets 3.5 mg/kg (delayed cladribine)
Study: 34137548
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream and oral tranexamic acid
Study: 34137548
Drug: Triple combination
Normalized name: Adrenergics in combination with anticholinergics incl. triple combinations with corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple combination cream alone
Study: 32334510
Drug: 0.5 μg·kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 μg·kg-1 DEX infusion (n=24)
Study: 32334510
Drug: 1.0 μg·kg-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 μg·kg-1 DEX infusion (n=25)
Study: 32334510
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (saline infusion, n=24)
Study: 35961362
Drug: RotaTeq (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RotaTeq (3 doses at 6, 10, and 14 weeks)
Study: 35961362
Drug: Rotarix (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix (2 doses at 6 and 10 weeks)
Study: 35961362
Drug: RotaTeq (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RotaTeq (2 doses at 6 and 10 weeks)
Study: 35961362
Drug: RotaTeq (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RotaTeq (3 doses)
Study: 35961362
Drug: Rotarix (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotarix (2 doses)
Study: 35775313
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy plus trastuzumab
Study: 32233747
Drug: Alcohol and
Normalized name: Polyvinyl alcohol and povidone only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol and other drug users (AOD)
Study: 35291694
Drug: IV alpha-1
Normalized name: alpha 1-antitrypsin
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV alpha-1 antitrypsin (AAT) 120 mg/kg weekly
Study: 34631601
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with emollients and topical corticosteroids plus dilute bleach baths (DBB)
Study: 34631601
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment with emollients and topical corticosteroids
Study: 32318749
Drug: Intrathecal dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal dexmedetomidine (5 μg, added to local anesthetics)
Study: 32318749
Drug: Intravenous dexmedetomidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexmedetomidine (1 μg/kg infused during 10 min before blockade)
Study: 35266342
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of inappropriate medications
Study: 35819327
Drug: Intravenous alteplase
Normalized name: Alteplase
DrugBank: Alteplase (DB00009)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alteplase added to EVT
Study: 34252576
Drug: Transluminal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transluminal injection of foam sclerotherapy (TLFS) with endovenous laser ablation (EVLA)
Study: 32297754
Drug: Computerized cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computerized cognitive-behavioral therapy (CBT4CBT)
Study: 34260595
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with benazepril (10 mg/day) and valsartan (160 mg/day)
Study: 34260595
Drug: Valsartan (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (320 mg/day)
Study: 34218992
Drug: Buprenorphine/naloxone (Bup/Nal)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine/naloxone (Bup/Nal) treatment for 12 weeks
Study: 34218992
Drug: Weekly drug
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly drug counseling
Study: 34174706
Drug: Unguided low
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unguided low intensity cognitive behaviour therapy
Study: 38729426
Drug: Subcutaneous administration
Normalized name: subcutaneous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous administration
Study: 33130235
Drug: Verinurad (9mg)
Normalized name: Verinurad
DrugBank: Verinurad (DB11873)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verinurad (9mg) plus febuxostat (80mg) once daily for 24 weeks
Study: 33130235
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo once daily for 24 weeks
Study: 32893745
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E and ginseng supplement (100 IU vitamin E, 67 mg Korean ginseng, and 40 mg Siberian ginseng)
Study: 36206298
Drug: Taxane-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane-based chemotherapy
Study: 35437223
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium chloride (MgCl2) for at least 4 months
Study: 35437223
Drug: Oral magnesium
Normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral magnesium chloride (MgCl2)
Study: 32679405
Drug: Transoral surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transoral surgery followed by low- or standard-dose, risk-adjusted post-operative therapy
Study: 33371454
Drug: High LF
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High LF (600 mg/day)
Study: 33371454
Drug: Low LF
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low LF (200 mg/day)
Study: 35900605
Drug: Test gel
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Test gel containing propolis extract, nanovitamin C, and nanovitamin E applied 3 times/day for 4 weeks
Study: 35900605
Drug: Control gel
Normalized name: SALICYLIC ACID 20 mg in 1 mL TOPICAL GEL [Walgreens Acne Control Gel]
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control gel applied 3 times/day for 4 weeks
Study: 33782413
Drug: Oral oestroprogestogen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oestroprogestogen contraceptive (OC)
Study: 33782413
Drug: Low-dose combination
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose combination of spironolactone-pioglitazone-metformin (SPIOMET)
Study: 33782413
Drug: Post-OC treatment
Normalized name: OC 8 Adult Acne
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-OC treatment
Study: 33782413
Drug: Post-SPIOMET treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-SPIOMET treatment
Study: 32291813
Drug: 100 units
Normalized name: heparin 100 units/mL injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 units of intradermal BTX‐A
Study: 32291813
Drug: Combined emollients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined emollients and topical mid‐potency steroid
Study: 36261447
Drug: NGF injection
Normalized name: Panthenol 1 g in 100 mL TOPICAL SOLUTION [NGF 574H HAIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: NGF injection in masseter muscle
Study: 36261447
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline injection in masseter muscle
Study: 32106832
Drug: Bupropion 75
Normalized name: buPROPion 75 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion 75 mg/day for the first three days and 150 mg/day (divided in two doses) till the end of the study at week 6.
Study: 32417634
Drug: Selenium yeast
Normalized name: Selenium Yeast
DrugBank: Selenium (DB11135)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium yeast (200 μg/day) and coenzyme Q10 (200 mg/day)
Study: 39016010
Drug: Intensive SBP
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive SBP treatment
Study: 34753667
Drug: Multi-component school-based
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-component school-based intervention (weekly supervised circuit exercise 30 min/week, health education session 10 min/week, lunchtime sports activities 20 min/week)
Study: 32563378
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (1 g loading dose followed by 3 g maintenance dose over 24 hours)
Study: 35147195
Drug: G-CSF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-CSF (300 µg, 1.8 ml)
Study: 35147195
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (1.8 ml)
Study: 34294550
Drug: Cholecalciferol supplementation
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol supplementation (50,000 IU weekly for 12 weeks)
Study: 34269257
Drug: Ketamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketamine infusion of 1 mg/kg/h
Study: 34269257
Drug: Propofol infusion
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol infusion of 1.5-6 mg/kg/h
Study: 32101145
Drug: Preoperative forced-air
Normalized name: air
DrugBank: Medical air (DB09337)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preoperative forced-air and intravenous fluid warming
Study: 35883082
Drug: Menaquinone‐7 (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menaquinone‐7 (90 µg/day)
Study: 36196478
Drug: FEP-medication group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEP-medication group (second-generation antipsychotic medication)
Study: 36196478
Drug: FEP-medication group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: FEP-medication group
Study: 34807661
Drug: Faster within-treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faster within-treatment improvement of PTSD symptoms
Study: 36242831
Drug: Intranasal oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intranasal oxytocin (24 IU), twice daily for three days
Study: 32610330
Drug: Cold Therapy
Normalized name: Deep Cold Therapy
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold Therapy (CT)
Study: 33397767
Drug: Bihormonal artificial
Normalized name: COLOR,ARTIFICIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bihormonal artificial pancreas (AP) therapy, 2-week duration
Study: 33397767
Drug: Open loop
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open loop control (patient's normal insulin pump therapy), 2-week duration
Study: 32044942
Drug: Incisional negative
Normalized name: GLYCERIN NEGATIVE CONTROL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Incisional negative pressure wound therapy (n=785)
Study: 33522891
Drug: Ice slurry
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice slurry ingestion (1.25 g·kg body mass‐1 at -1°C) during HA training
Study: 36198994
Drug: Fluconazole (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole (150 mg) with 30 placebo capsules of probiotic
Study: 36198994
Drug: Probiotic (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic (30 capsules containing 1 × 10^9 CFU/g LA‐5) with 1 fluconazole placebo capsule
Study: 32701225
Drug: Ocriplasmin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin infusion during robot-assisted retinal vein cannulation
Study: 32701225
Drug: Ocriplasmin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocriplasmin infusion
Study: 35247321
Drug: ZY-19489 1500
Normalized name: ZY-19489
DrugBank: ZY19489 (DB18062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZY-19489 1500 mg
Study: 35247321
Drug: ZY-19489 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZY-19489 (300 mg) in fed state
Study: 35247321
Drug: ZY-19489 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZY-19489 (300 mg) in fasted state
Study: 35247321
Drug: ZY-19489 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZY-19489 (200 mg)
Study: 35247321
Drug: ZY-19489 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZY-19489 (300 mg)
Study: 35247321
Drug: ZY-19489 (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZY-19489 (900 mg)
Study: 35247321
Drug: Pharmacokinetic-Pharmacodynamic model
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacokinetic-Pharmacodynamic model simulation for 1100 mg
Study: 35450456
Drug: 0.30% sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.30% sodium hyaluronate ocular gel
Study: 35445520
Drug: SlowMo therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: SlowMo therapy
Study: 34648352
Drug: FOLFOX‐HAIC (oxaliplatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX‐HAIC (oxaliplatin 130 mg/m2, leucovorin 400 mg/m2, fluorouracil bolus 400 mg/m2 on day 1, and fluorouracil infusion 2,400 mg/m2 for 24 hours, once every 3 weeks)
Study: 34648352
Drug: TACE (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TACE (epirubicin 50 mg, lobaplatin 50 mg, and lipiodol and polyvinyl alcohol particles)
Study: 35237342
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin combined with vitamin E
Study: 34701332
Drug: S1 maintenance
Normalized name: cenobamate
DrugBank: Cenobamate (DB06119)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: S1 maintenance therapy
Study: 34856826
Drug: Acupuncture (standardized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (standardized protocol, twice per week for 5 weeks)
Study: 34678887
Drug: Epidural block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural block with 75 mg of bupivacaine plus 50 μg of fentanyl
Study: 34678887
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia with 15 mg of bupivacaine and 50 μg fentanyl
Study: 34678887
Drug: Saddle block
Normalized name: Saddle Block-22
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saddle block with 15 mg of bupivacaine and 50 μg of fentanyl
Study: 34768161
Drug: K562/GM‐CSF vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: K562/GM‐CSF vaccine
Study: 32087684
Drug: Oral Sucrosomial®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Sucrosomial® iron
Study: 32087684
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) iron gluconate
Study: 33973256
Drug: Faces with
Normalized name: Face Up with Sulfur
Approvals — FDA: no, EMA: no, PMDA: no
Description: Faces with distinctive features (e.g., tattoos)
Study: 33245807
Drug: Cues to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cues to experience nature (e.g., smell flowers, observe wildlife, turn off your phone)
Study: 33245807
Drug: Cues to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cues to experience nature (e.g., smell and touch natural elements)
Study: 35135308
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist therapy
Study: 35135308
Drug: Uninterrupted apixaban
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Uninterrupted apixaban and Vitamin K antagonist therapy
Study: 34846698
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment only
Study: 35713447
Drug: Institutional antiemetic
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Institutional antiemetic therapy alone
Study: 35713447
Drug: Institutional antiemetic
Normalized name: vilanterol
DrugBank: Vilanterol (DB09082)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Institutional antiemetic therapy in combination with ginger (2 different concentrations)
Study: 35790016
Drug: Standard chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemotherapy (control arm of five RCTs: ASCENT 2, VENICE, CELGENE/MAINSAIL, ENTHUSE 14, ENTHUSE 33)
Study: 36054319
Drug: Clobetasol Propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol Propionate ointment
Study: 37753555
Drug: Traditional oral
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional oral hygiene instructions (OHI)
Study: 34651102
Drug: Pamphlet of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamphlet of drug abuse prevention
Study: 35501772
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) program
Study: 36028775
Drug: Individual nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual nutrition therapy (five in-person visits and three phone calls) and freely delivered energy- and protein-rich foods
Study: 33636344
Drug: Behavioral intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral intervention including nudges within the electronic health record (EHR) such as accountable justification, precommitment to address high-risk prescriptions, and PainTracker.
Study: 33212438
Drug: IG3: combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: IG3: combination of IG1 and IG2
Study: 32798761
Drug: Layer‐by‐layer wound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Layer‐by‐layer wound irrigation with gentamicin‐saline solution
Study: 32798761
Drug: Wound irrigation
Normalized name: Prontosan Wound Irrigation Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wound irrigation with saline solution
Study: 32359506
Drug: Bortezomib-lenalidomide-dexamethasone (VRD)
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib-lenalidomide-dexamethasone (VRD) consolidation therapy
Study: 34527078
Drug: Eprosartan (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eprosartan (600 mg daily)
Study: 33263418
Drug: Margetuximab plus
Normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Margetuximab plus retifanlimab with/without chemotherapy
Study: 33263418
Drug: Margetuximab plus
Normalized name: Margetuximab
DrugBank: Margetuximab (DB14967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Margetuximab plus tebotelimab with chemotherapy
Study: 34341242
Drug: Chemomechanical removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemomechanical removal (Papaya® gel)
Study: 32372118
Drug: Intravenous TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous TXA (15 mg/kg)
Study: 32372118
Drug: Intra-articular TXA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular TXA (2 g)
Study: 34030169
Drug: Sertraline (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (50 mg daily, up-titrated after 25 mg daily for 1 week)
Study: 32029903
Drug: Naltrexone (NTX)
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naltrexone (NTX) treatment
Study: 35781129
Drug: Single, high‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, high‐dose intravenous iron therapy (20 mg/kg ferric derisomaltose)
Study: 35781129
Drug: Oral iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral iron supplementation (100 mg ferrous sulphate orally twice daily)
Study: 34684650
Drug: Water supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water supplementation group (1000 mL purified water)
Study: 34684650
Drug: Water supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water supplementation group (500 mL purified water)
Study: 34684650
Drug: Water supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water supplementation group (200 mL purified water)
Study: 34618889
Drug: Preoperative paravertebral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative paravertebral block with 0.35 ml/kg 0.75% ropivacaine
Study: 32086874
Drug: Ethmoidal drug-eluting
Normalized name: Fraxinus velutina pollen
DrugBank: Fraxinus velutina pollen (DB10455)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ethmoidal drug-eluting stent (DES) with triamcinolone acetonide stents (n = 34)
Study: 32086874
Drug: Topical intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intranasal corticosteroid (triamcinolone acetonide nasal spray) (n = 29)